bioAffinity Technologies Q3 2026 earnings

BIAF · 2026-11-06 17:28 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue declined 26% YoY to $1.07M, while operating expenses fell 22% YoY to $4.58M, resulting in a wider net loss of $5.28M.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1.07M-26%-29%Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin not stated in the 8-K
  • Operating expenses $4.58M (-22% YoY)
  • One-offs in the quarter Loss on warrant liabilities $1.22M; Offering costs allocated to warrant liability $0.53M
  • Effective tax rate not stated in the 8-K
  • Non-GAAP bridge No reconciliation provided.

KPIs

MetricActualPrior quarterPrior yearChange
Weighted average common shares outstanding896,2715,226,75371,090+71%
Net loss per common share, basic and diluted$-5.89$-0.64$-71.05+819%

Guidance

not stated in the 8-K

What drove it

  • Revenue story Revenue decreased 26% YoY to $1.07M, primarily due to a decrease in average reimbursement per CyPath Lung test and a slight decline in total cases completed at PPLS, partially offset by internal business changes at three research clients.
  • EPS story Net loss per share widened to $-5.89 from $-71.05 YoY, driven by a 71% increase in weighted average shares outstanding and a $1.22M loss on warrant liabilities.
  • One-off check Loss on warrant liabilities $1.22M (vs $2.75M loss in prior year) and offering costs allocated to warrant liability $0.53M.

The good

  • Operating expenses decreased 22% YoY to $4.58M
  • Cash balance increased 5% QoQ to $2.55M

The bad

  • Revenue decreased 26% YoY to $1.07M
  • Net loss widened 4% YoY to $5.28M
  • Weighted average shares outstanding increased 71% YoY

The ugly

  • none

Open questions

  • What is the expected timeline to restore additional accounts and improve reimbursement levels?
  • How will the $4.0M financing completed subsequent to quarter-end impact the FY2026 cash runway?
Full release

bioAffinity Technologies (BIAF) earnings release, November 6, 2026

bioAffinity Technologies, Inc. (BIAF) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1 bioAffinity

Technologies Reports Third Quarter 2026 Results and Continued Momentum in CyPath®

Lung Commercialization

CyPath®

Lung test unit sales double year to date over 2025, with solid gains in physician utilization and recurring orders; testing revenue increases

79% year-to-date

Company advances precision medicine pipeline with new asthma and COPD research, collaboration with Pictor and continued development of topical skin cancer therapeutics

SAN

ANTONIO, Texas – November 6, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease and topically delivered therapeutics for skin cancer, today reported financial results and business highlights for the third quarter (Q3) ended September 30, 2026.

Q3

2026 Highlights and Recent Events

Management

Commentary

“Our third-quarter results reflect CyPath Lung’s continued momentum in addressing the critical need for early lung cancer detection, driven by both new physicians ordering the test and increased use by existing customers. We believe this growth reflects increasing physician engagement and recognition of the role CyPath Lung can play in managing care for patients at risk for lung cancer. We are also advancing its potential use in surveillance following curative-intent treatment, where CyPath Lung could complement imaging in monitoring for recurrence and new cancers,” said Maria Zannes, President of CEO of bioAffinity Technologies. “Peer-to-peer education and growing clinical experience with the test remain important drivers of adoption, while our longitudinal study is designed to generate robust, real-world data across multiple sites to further evaluate how CyPath Lung may support risk assessment and clinical decision-making. Together, these efforts advance our objective of establishing CyPath Lung as a standard of care for evaluating patients at risk for lung cancer.

“We continue to build the foundation for long-term growth. Beyond lung cancer, we are advancing our platform to take advantage of precision medicine opportunities in asthma and COPD, where sputum-based analysis may help characterize lung inflammation and help physicians better match individual patients to available treatments, including Tezspire, Dupixent and Nucala. The tests we are developing are designed to meet a critical need for precision diagnostics in the multi-billion-dollar asthma and COPD therapeutic markets.

“Our patent portfolio now includes 22 awarded U.S. and foreign patents and 36 pending applications. The recent Hong Kong patent and the Japanese patent allowance, once awarded, are important additions to our patent portfolio. Our distribution agreement with AvMEDICAL is intended to expand our reach into government healthcare markets, including the VA, where the substantial burden of lung cancer underscores the need for more effective ways to evaluate pulmonary nodules and improve patient outcomes.

Ms.

Zannes concluded, “Our priorities remain disciplined execution, expanding commercial adoption and advancing our clinical and research programs. We are also pursuing topical therapeutic approaches for squamous and basal cell skin cancers based on promising findings involving the CD320 and LRP2 receptors. We believe our expertise in flow cytometry, automated data analysis and siRNA technology provides a foundation for developing differentiated products across these markets. Together, these programs demonstrate our commitment to translating scientific innovation into meaningful new opportunities for patients and the Company.”

Third

Quarter 2026 Financial Results

Total revenue for the quarter ended September 30, 2026, was approximately $1.1 million, compared with approximately $1.4 million for the same period in 2025. The decrease is due primarily to a decrease in average reimbursement per CyPath Lung test and a slight decline in total cases completed at Precision Pathology Laboratory Services (PPLS) compared to the same period in 2025, in part due to internal business changes at three PPLS research clients. Multiple accounts previously serviced under these clients have since returned to PPLS. The Company is working to restore additional accounts and improve reimbursement levels.

Net loss for the quarter ended September 30, 2026, was approximately $5.3 million, compared with approximately $5.1 million for the third quarter of 2025. The increase in net loss is primarily due to the increase in loss from operations of approximately $3.5 million from approximately $2.3 million in the prior-year quarter, partially offset by a $1.2 million loss from the change in fair value of warrants, compared with a $2.7 million loss in the prior-year quarter.

Cash and cash equivalents were approximately $2.6 million as of September 30, 2026, compared with approximately $6.4 million at December 31,

2025. Subsequent to quarter-end, the Company completed a financing that generated approximately $4.0 million in gross proceeds.

Operating expenses for the third quarter of 2026 were approximately $4.6 million, compared with approximately $3.7 million in the third quarter of 2025.

About

CyPath Lung

CyPath

Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath Lung analyzes the lung microenvironment by using advanced flow cytometry and proprietary artificial intelligence

(AI) to identify cell populations in patient sputum that indicate malignancy. The test incorporates a novel fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a published clinical trial of high-risk patients, CyPath Lung... (truncated)NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath

Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings. For more information, visit www.cypathlung.com.

About bioAffinity Technologies, Inc. bioAffinity

Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision

Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement

Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended September 30, — Unaudited Condensed Consolidated Statements of Operations

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net revenue1,070,2801,446,0663,932,3864,569,146
Operating expenses:
Direct costs and expenses1,114,176942,2113,130,6493,326,673
Research and development389,122330,5891,100,4041,009,347
Clinical development251,043143,3111,060,968410,943
Selling, general and administrative2,759,7692,209,4418,859,9616,876,551
Depreciation and amortization66,842113,360242,916381,177
Total operating expenses4,580,9523,738,91214,394,89812,004,691
Loss from operations-3,510,672-2,292,846-10,462,512-7,435,545
Other income (expense):
Interest income4,7341,08818,1183,655
Interest expense-10,713-5,358-37,123-31,303
Other income3,1445136,51638,568
Other expense-13,072-3,839-48,270-16,828
Offering costs allocated to warrant liability-532,209-532,209-479,696
Loss on warrant liabilities-1,218,235-2,747,460-1,218,235-3,810,278
Total other income (expense), net-1,766,351-2,755,056-1,811,203-4,295,882
Net loss before provision for income tax expense-5,277,023-5,047,902-12,273,715-11,731,427
Income tax expense3,18240,861
Net loss-5,277,023-5,051,084-12,273,715-11,772,288
Net loss per common share, basic and diluted-5.89-71.05-23.72-219.47
Weighted average common shares outstanding896,27171,090517,49053,640

Balance Sheet

September 30, 2026 — Condensed Consolidated Balance Sheets

September 30, 2026 – (unaudited)December 31, 2025
Current assets:
Cash and cash equivalents2,550,0346,449,782
Accounts and other receivables, net742,144541,962
Inventory108,75453,548
Prepaid expenses and other current assets427,230519,916
Total current assets3,828,1627,565,208
Non-current assets:
Property and equipment, net362,359265,593
Operating lease right-of-use asset, net730,572334,289
Finance lease right-of-use asset, net538,326661,575
Goodwill1,404,4861,404,486
Intangible assets, net673,056716,806
Other assets16,71012,815
Total assets7,553,67110,960,772
Current liabilities:
Accounts payable949,018761,901
Accrued expenses1,143,2271,717,989
Unearned revenue48,87442,405
Operating lease liability, current portion168,534139,220
Finance lease liability, current portion78,926139,490
Notes payable, current portion144,715105,161
Total current liabilities2,533,2942,906,166
Non-current liabilities:
Operating lease liability, net of current portion596,086202,878
Finance lease liability, net of current portion475,772532,759
Notes payable, net of current portion33,95841,313
Total liabilities3,639,1103,683,116
Stockholders’ equity:
Preferred Stock, par value $0.001 per share; 20,000,000 shares authorized; 150 shares and 700 shares issued and outstanding at September 30, 2026, and December 31, 2025, respectively11
Common Stock, par value $0.007 per share; 350,000,000 shares authorized; 1,166,625 and 299,826 issued and outstanding at September 30, 2026, and December 31, 2025, respectively8,1662,097
Additional paid-in capital84,734,17375,829,622
Accumulated deficit-80,827,779-68,554,064
Total stockholders’ equity3,914,5617,277,656
Total liabilities and stockholders’ equity7,553,67110,960,772

Cash Flow

From the 10-Q · Unaudited Condensed Consolidated Statements of Cash Flows

2026 – Nine Months Ended September 30,2025 – Nine Months Ended September 30,
Cash flows from operating activities
Net loss-12,273,715-11,772,288
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization242,916381,177
Stock-based compensation expense938,174605,355
Issuance of Placement Agent warrants94,709
Loss on warrant liabilities1,218,2353,810,278
Changes in operating assets and liabilities:
Accounts and other receivables-200,182690,214
Inventory-55,206-7,626
Prepaid expenses and other assets88,791-30,331
Accounts payable187,117-46,550
Accrued expenses-574,762-414,175
Unearned revenue6,46913,511

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws.

Words such as “may,” “might,” “will,” “should,” “believe,” “expect,”

“anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,”

“plan,” “intend” and similar expressions may identify forward-looking statements, although not all forward-looking statements contain these words. Actual results could differ materially from those expressed or implied because of risks and uncertainties, including the Company’s ability to expand the commercial adoption of CyPath Lung and capitalize on government healthcare market opportunities; the timing, cost, enrollment and outcome of clinical studies; the possibility that preliminary, in vitro or study-specific findings will not be replicated or translate into safe and effective therapies or commercial products for asthma, COPD or skin cancer; the need for further validation of new applications, including surveillance; the extent and timing of physician adoption, repeat utilization and customer retention; payer coverage, reimbursement rates and collections; and the Company’s ability to obtain, maintain and enforce intellectual property rights. Additional risks are discussed in the Company’s Annual Report on Form 10-K for the year ended

December 31, 2025, and subsequent SEC filings, including its reports on Forms 10-Q and 8-K. Forward-looking statements reflect expectations and assumptions only as of the date of this release. Readers should not place undue reliance on them. The Company undertakes no obligation to update these statements, except as required by applicable law.

Contact bioAffinity

Technologies

Julie

Anne Overton

Director of Communications investors@bioaffinitytech.com bioAffinity

Technologies, Inc.

Condensed

Consolidated Balance Sheets bioAffinity

Technologies, Inc.

Unaudited

Condensed Consolidated Statements of Operations

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · bioAffinity Technologies earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.